Stratagene's Profits up 25 Percent in Q1 on Steady Sales | GenomeWeb
NEW YORK (GenomeWeb News) - Stratagene yesterday said first-quarter revenues were steady as R&D spending dipped nearly 10 percent and profit increased 25 percent.
 
Total receipts for the three months ended March 31, 2007, rose slightly to $24.4 million from $24.3 million year over year.
 
R&D spending fell slightly to $3.1 million from $3.4 million.
 
The company said net income rose to $1.4 million from $1.1 million in the year-ago period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.